866-997-4948(US-Canada Toll Free)

Migraine - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Nov 2016

Category :

Pharmaceutical

No. of Pages : 221 Pages

Migraine - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Migraine Pipeline Review, H2 2016, provides an overview of the Migraine (Central Nervous System) pipeline landscape.

Migraine is a disorder characterized by repeated attacks of severe headache. A migraine headache causes throbbing or pulsating pain, usually on only one side of the head. These headaches are often associated with nausea, vomiting, and extreme sensitivity to light and sound. Symptoms include problems speaking, tingling in face, arms, and shoulders, pain behind one of the eyes and pain that gets worse with routine physical activity.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Migraine Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Migraine (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Migraine (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Migraine and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 12, 14, 14, 20, 8 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 3 molecules, respectively.Migraine.

Migraine (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Migraine (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Migraine (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Migraine (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Migraine (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Migraine (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Migraine (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Migraine (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Migraine Overview 10
Therapeutics Development 11
Pipeline Products for Migraine - Overview 11
Pipeline Products for Migraine - Comparative Analysis 12
Migraine - Therapeutics under Development by Companies 13
Migraine - Therapeutics under Investigation by Universities/Institutes 17
Migraine - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Unknown Stage Products 21
Migraine - Products under Development by Companies 22
Migraine - Products under Investigation by Universities/Institutes 26
Migraine - Companies Involved in Therapeutics Development 27
Achelios Therapeutics Inc 27
Acorda Therapeutics Inc 28
Afferent Pharmaceuticals Inc 29
Alder Biopharmaceuticals Inc 30
Allergan Plc 31
Amgen Inc 32
Aralez Pharmaceuticals Inc 33
Astellas Pharma Inc 34
Biofrontera AG 35
BioHealthonomics Inc 36
Bristol-Myers Squibb Company 37
Charleston Laboratories Inc 38
CoLucid Pharmaceuticals Inc 39
Corium International Inc 40
Eli Lilly and Company 41
Impel NeuroPharma Inc 42
InStar Technologies AS 43
Klaria Pharma Holding AB 44
Medestea Research & Production SpA 45
Merck & Co Inc 46
Mithra Pharmaceuticals SA 47
Monosol Rx LLC 48
NAL Pharmaceuticals Ltd 49
Noxxon Pharma AG 50
Otsuka Holdings Co Ltd 51
Promius Pharma LLC 52
RedHill Biopharma Ltd 53
Revance Therapeutics Inc 54
Shin Nippon Biomedical Laboratories Ltd 55
Strategic Science & Technologies LLC 56
Suda Ltd 57
Teva Pharmaceutical Industries Ltd 58
TheraJect Inc 59
Tonix Pharmaceuticals Holding Corp 60
Trevena Inc 61
Trigemina Inc 62
TrioxBio Inc 63
Vertex Pharmaceuticals Inc 64
Xenon Pharmaceuticals Inc 65
Zosano Pharma Corp 66
Migraine - Therapeutics Assessment 67
Assessment by Monotherapy Products 67
Assessment by Combination Products 68
Assessment by Target 69
Assessment by Mechanism of Action 74
Assessment by Route of Administration 79
Assessment by Molecule Type 81
Drug Profiles 83
(dextromethorphan + quinidine sulfate) - Drug Profile 83
(naproxen sodium + sumatriptan succinate) - Drug Profile 88
(promethazine [INN] + sumatriptan succinate) - Drug Profile 90
AA-71 - Drug Profile 91
AF-130 - Drug Profile 92
AGN-241689 - Drug Profile 93
ALD-1910 - Drug Profile 94
ALD-403 - Drug Profile 95
AMG-301 - Drug Profile 99
AST-003 - Drug Profile 100
Atogepant - Drug Profile 101
BF-1 - Drug Profile 102
C-012 - Drug Profile 103
cloxyquin - Drug Profile 104
Deina - Drug Profile 105
dexisometheptene - Drug Profile 106
DFN-02 - Drug Profile 107
DFN-10 - Drug Profile 108
DFN-14 - Drug Profile 109
DFN-15 - Drug Profile 110
DFN-19 - Drug Profile 111
DFN-42 - Drug Profile 112
dihydroergotamine mesylate - Drug Profile 113
dihydroergotamine mesylate - Drug Profile 118
DIS-COM-TROP - Drug Profile 119
DORA-12 - Drug Profile 120
Drug 1 for Migraine and Cancer Pain - Drug Profile 121
Drug 2 for Migraine and Cancer Pain - Drug Profile 122
Drug 3 for Migraine and Cancer Pain - Drug Profile 123
Drug for Migraine - Drug Profile 124
Drug for Migraine and Cancer Pain - Drug Profile 125
erenumab - Drug Profile 126
Estetrol - Drug Profile 129
flunarizine hydrochloride - Drug Profile 132
galcanezumab - Drug Profile 133
histamine dihydrochloride - Drug Profile 135
ketoprofen - Drug Profile 136
KL-00204 - Drug Profile 138
lasmiditan succinate - Drug Profile 139
MK-8031 - Drug Profile 144
MTR-106 - Drug Profile 145
Nociceptin - Drug Profile 146
NOXL-41 - Drug Profile 147
NXN-188 - Drug Profile 148
NXN-462 - Drug Profile 150
oxytocin - Drug Profile 151
picotamide - Drug Profile 153
propofol hemisuccinate - Drug Profile 154
Protein to Activate Insulin Like Growth Factor 1 Receptor for Migraine - Drug Profile 155
rizatriptan benzoate - Drug Profile 156
rizatriptan benzoate - Drug Profile 159
rizatriptan benzoate - Drug Profile 160
RT-001 - Drug Profile 161
Small Molecule to Antagonize CALCRL for Migraine - Drug Profile 163
Small Molecule to Antagonize CGRP Receptor for Migraine - Drug Profile 164
Small Molecule to Antagonize Kappa Opioid Receptor for Migraine - Drug Profile 165
Small Molecule to Inhibit CGRP for Migraine - Drug Profile 166
Small Molecule to Inhibit GABA Transaminase for Migraine and Status Epilepticus - Drug Profile 167
Small Molecule to Inhibit nNOS and NET for Migraine and Neuropathic Pain - Drug Profile 168
Small Molecules to Agonize CB2 for Chronic Pain and Migraine - Drug Profile 169
Small Molecules to Antagonize Calcitonin Gene-Related Peptide for Migraine - Drug Profile 170
Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for IBS and Migraine - Drug Profile 171
Small Molecules to Inhibit CGRP for Migraine and Osteoarthritis Pain - Drug Profile 172
SST-8055 - Drug Profile 173
sumatriptan succinate - Drug Profile 174
sumatriptan succinate - Drug Profile 176
sumatriptan succinate - Drug Profile 177
sumatriptan succinate - Drug Profile 178
TEV-48125 - Drug Profile 179
Tribarcina - Drug Profile 183
TRV-250 - Drug Profile 184
ubrogepant - Drug Profile 185
zolmitriptan - Drug Profile 187
zolmitriptan - Drug Profile 188
zolmitriptan - Drug Profile 190
zolmitriptan - Drug Profile 191
Migraine - Dormant Projects 192
Migraine - Discontinued Products 199
Migraine - Product Development Milestones 200
Featured News & Press Releases 200
Appendix 215
Methodology 215
Coverage 215
Secondary Research 215
Primary Research 215
Expert Panel Validation 215
Contact Us 215
Disclaimer 216

List of Tables
Number of Products under Development for Migraine, H2 2016 16
Number of Products under Development for Migraine - Comparative Analysis, H2 2016 17
Number of Products under Development by Companies, H2 2016 19
Number of Products under Development by Companies, H2 2016 (Contd..1) 20
Number of Products under Development by Companies, H2 2016 (Contd..2) 21
Number of Products under Investigation by Universities/Institutes, H2 2016 22
Comparative Analysis by Late Stage Development, H2 2016 23
Comparative Analysis by Clinical Stage Development, H2 2016 24
Comparative Analysis by Early Stage Development, H2 2016 25
Comparative Analysis by Unknown Stage Development, H2 2016 26
Products under Development by Companies, H2 2016 27
Products under Development by Companies, H2 2016 (Contd..1) 28
Products under Development by Companies, H2 2016 (Contd..2) 29
Products under Development by Companies, H2 2016 (Contd..3) 30
Products under Investigation by Universities/Institutes, H2 2016 31
Migraine - Pipeline by Achelios Therapeutics Inc, H2 2016 32
Migraine - Pipeline by Acorda Therapeutics Inc, H2 2016 33
Migraine - Pipeline by Afferent Pharmaceuticals Inc, H2 2016 34
Migraine - Pipeline by Alder Biopharmaceuticals Inc, H2 2016 35
Migraine - Pipeline by Allergan Plc, H2 2016 36
Migraine - Pipeline by Amgen Inc, H2 2016 37
Migraine - Pipeline by Aralez Pharmaceuticals Inc, H2 2016 38
Migraine - Pipeline by Astellas Pharma Inc, H2 2016 39
Migraine - Pipeline by Biofrontera AG, H2 2016 40
Migraine - Pipeline by BioHealthonomics Inc, H2 2016 41
Migraine - Pipeline by Bristol-Myers Squibb Company, H2 2016 42
Migraine - Pipeline by Charleston Laboratories Inc, H2 2016 43
Migraine - Pipeline by CoLucid Pharmaceuticals Inc, H2 2016 44
Migraine - Pipeline by Corium International Inc, H2 2016 45
Migraine - Pipeline by Eli Lilly and Company, H2 2016 46
Migraine - Pipeline by Impel NeuroPharma Inc, H2 2016 47
Migraine - Pipeline by InStar Technologies AS, H2 2016 48
Migraine - Pipeline by Klaria Pharma Holding AB, H2 2016 49
Migraine - Pipeline by Medestea Research & Production SpA, H2 2016 50
Migraine - Pipeline by Merck & Co Inc, H2 2016 51
Migraine - Pipeline by Mithra Pharmaceuticals SA, H2 2016 52
Migraine - Pipeline by Monosol Rx LLC, H2 2016 53
Migraine - Pipeline by NAL Pharmaceuticals Ltd, H2 2016 54
Migraine - Pipeline by Noxxon Pharma AG, H2 2016 55
Migraine - Pipeline by Otsuka Holdings Co Ltd, H2 2016 56
Migraine - Pipeline by Promius Pharma LLC, H2 2016 57
Migraine - Pipeline by RedHill Biopharma Ltd, H2 2016 58
Migraine - Pipeline by Revance Therapeutics Inc, H2 2016 59
Migraine - Pipeline by Shin Nippon Biomedical Laboratories Ltd, H2 2016 60
Migraine - Pipeline by Strategic Science & Technologies LLC, H2 2016 61
Migraine - Pipeline by Suda Ltd, H2 2016 62
Migraine - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2016 63
Migraine - Pipeline by TheraJect Inc, H2 2016 64
Migraine - Pipeline by Tonix Pharmaceuticals Holding Corp, H2 2016 65
Migraine - Pipeline by Trevena Inc, H2 2016 66
Migraine - Pipeline by Trigemina Inc, H2 2016 67
Migraine - Pipeline by TrioxBio Inc, H2 2016 68
Migraine - Pipeline by Vertex Pharmaceuticals Inc, H2 2016 69
Migraine - Pipeline by Xenon Pharmaceuticals Inc, H2 2016 70
Migraine - Pipeline by Zosano Pharma Corp, H2 2016 71
Assessment by Monotherapy Products, H2 2016 72
Assessment by Combination Products, H2 2016 73
Number of Products by Stage and Target, H2 2016 75
Number of Products by Stage and Mechanism of Action, H2 2016 80
Number of Products by Stage and Route of Administration, H2 2016 85
Number of Products by Stage and Molecule Type, H2 2016 87
Migraine - Dormant Projects, H2 2016 197
Migraine - Dormant Projects (Contd..1), H2 2016 198
Migraine - Dormant Projects (Contd..2), H2 2016 199
Migraine - Dormant Projects (Contd..3), H2 2016 200
Migraine - Dormant Projects (Contd..4), H2 2016 201
Migraine - Dormant Projects (Contd..5), H2 2016 202
Migraine - Dormant Projects (Contd..6), H2 2016 203
Migraine - Discontinued Products, H2 2016 204

List of Figures
Number of Products under Development for Migraine, H2 2016 16
Number of Products under Development for Migraine - Comparative Analysis, H2 2016 17
Number of Products under Development by Companies, H2 2016 18
Number of Products under Investigation by Universities/Institutes, H2 2016 22
Comparative Analysis by Late Stage Development, H2 2016 23
Comparative Analysis by Clinical Stage Development, H2 2016 24
Comparative Analysis by Early Stage Products, H2 2016 25
Assessment by Monotherapy Products, H2 2016 72
Assessment by Combination Products, H2 2016 73
Number of Products by Top 10 Targets, H2 2016 74
Number of Products by Stage and Top 10 Targets, H2 2016 74
Number of Products by Top 10 Mechanism of Actions, H2 2016 79
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 79
Number of Products by Routes of Administration, H2 2016 84
Number of Products by Stage and Routes of Administration, H2 2016 84
Number of Products by Molecule Types, H2 2016 86
Number of Products by Stage and Molecule Types, H2 2016 86

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *